圣达生物(603079) - 2019 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 121,191,303.02, representing a 2.74% increase year-on-year[5] - Net profit attributable to shareholders decreased by 41.32% to CNY 14,112,251.27 compared to the same period last year[5] - Basic and diluted earnings per share both decreased by 38.10% to CNY 0.13[5] - The company reported a net profit margin improvement, with net profit for Q1 2019 expected to be higher than the previous year, although specific figures were not disclosed[25] - The company's operating revenue for Q1 2019 was CNY 74,696,718.35, a decrease of 11.5% compared to CNY 84,425,860.00 in Q1 2018[29] - The net profit for Q1 2019 was CNY 7,304,641.17, down 76.8% from CNY 31,446,679.73 in Q1 2018[30] - The total profit for Q1 2019 was CNY 8,529,909.26, a decrease of 77.9% compared to CNY 36,952,310.15 in Q1 2018[30] Assets and Liabilities - Total assets increased by 6.63% to CNY 1,335,768,131.04 compared to the end of the previous year[5] - The company's total liabilities as of March 31, 2019, amounted to CNY 492,831,027.57, compared to CNY 424,293,547.93 at the end of 2018, indicating a growth of 16.09%[22] - Total assets reached CNY 1,066,100,603.03 as of March 31, 2019, compared to CNY 954,610,826.55 at the end of 2018, marking an increase of 11.68%[24] - Shareholders' equity totaled CNY 776,801,986.33 as of March 31, 2019, up from CNY 769,497,345.16 at the end of 2018, reflecting a growth of 0.42%[24] - Current assets totaled ¥614,694,473.33, up from ¥569,776,515.06 in the previous period[20] - The company reported a total asset value of 954,610,826.55, indicating a strong financial position[44] Cash Flow - Net cash flow from operating activities was negative at CNY -342,344.60, a decline of 133.46% compared to the previous year[5] - The net cash flow from operating activities for Q1 2019 was approximately -¥342,344.60, compared to a positive cash flow of ¥1,023,246.79 in Q1 2018[32] - The total cash inflow from investment activities in Q1 2019 was approximately ¥15.65 million, significantly lower than ¥92.55 million in Q1 2018, representing a decline of 83.1%[33] - The cash inflow from financing activities in Q1 2019 was approximately ¥117 million, a substantial increase from ¥23 million in Q1 2018, reflecting a growth of 409%[33] - The net cash flow from financing activities in Q1 2019 was approximately ¥58.51 million, compared to ¥8.49 million in Q1 2018, showing a significant improvement[33] Shareholder Information - The number of shareholders reached 8,514, with the top ten shareholders holding a combined 73.10% of shares[9] - The largest shareholder, Zhejiang Shengda Group Co., Ltd., holds 28.94% of shares, with 4,500,000 shares pledged[9] Expenses - Total operating costs for Q1 2019 were CNY 109,002,675.83, up 20.19% from CNY 90,653,945.98 in Q1 2018[26] - Sales expenses increased by 100.26% to ¥4,615,797.03, primarily due to higher transportation costs[13] - Financial expenses decreased by 55.12% to ¥3,935,073.83, mainly due to reduced exchange losses from currency fluctuations[13] - Research and development expenses increased to CNY 2,514,441.54 in Q1 2019, up 35.2% from CNY 1,859,772.56 in Q1 2018[30] Other Income and Gains - The company reported a total of CNY 4,253,012.77 in non-recurring gains and losses for the period[8] - Other income surged by 876.09% to ¥4,862,045.84, primarily from increased government subsidies received[13] - The company reported other income of CNY 3,701,248.76 in Q1 2019, a significant increase from CNY 159,320.42 in Q1 2018[30] Borrowings and Financial Instruments - Short-term borrowings increased by 74.72% to CNY 178,834,000.00 compared to the beginning of the year[12] - Cash obtained from borrowings increased by 408.70% to ¥117,000,000.00, primarily due to increased bank loans[15] - The company has implemented new financial instrument standards effective January 1, 2019, impacting the measurement of financial assets[45] - The company adjusted its financial statements to reflect the cumulative impact of the new financial standards[45]